1. Home
  2. LPG vs CRVS Comparison

LPG vs CRVS Comparison

Compare LPG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dorian LPG Ltd.

LPG

Dorian LPG Ltd.

HOLD

Current Price

$38.41

Market Cap

1.5B

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.38

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPG
CRVS
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
LPG
CRVS
Price
$38.41
$14.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$39.33
$30.17
AVG Volume (30 Days)
384.5K
1.1M
Earning Date
05-21-2026
05-07-2026
Dividend Yield
8.32%
N/A
EPS Growth
N/A
48.04
EPS
2.64
N/A
Revenue
$353,341,476.00
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.60
$3.17
52 Week High
$39.00
$26.95

Technical Indicators

Market Signals
Indicator
LPG
CRVS
Relative Strength Index (RSI) 66.72 43.64
Support Level $29.47 $14.38
Resistance Level N/A $19.21
Average True Range (ATR) 1.29 1.21
MACD 0.28 -0.03
Stochastic Oscillator 83.55 6.62

Price Performance

Historical Comparison
LPG
CRVS

About LPG Dorian LPG Ltd.

Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: